Business ❯ Pharmaceuticals ❯ Drug Development

Clinical Research

Wave Life Sciences Funding Sources Pharmaceutical Industry Trends AstraZeneca Regulatory Affairs Japanese Pharmaceutical Companies

Edgewise Reports Favorable Interim Safety in Phase 2 HCM Trial of EDG-7500

The readout underscores a clean cardiac safety profile, preserving the timeline for full Part D data in Q2 2026.

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

FDA Qualifies First AI Tool for MASH Drug Trials

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

Study Finds Most With New Focal Epilepsy Need a Year to Gain Seizure Control